Previous close | 10,742.00 |
Open | 10,756.00 |
Bid | 10,704.00 x 0 |
Ask | 10,706.00 x 0 |
Day's range | 10,674.00 - 10,780.00 |
52-week range | 9,461.00 - 12,392.00 |
Volume | |
Avg. volume | 2,925,078 |
Market cap | 165.872B |
Beta (5Y monthly) | 0.17 |
PE ratio (TTM) | 35.43 |
EPS (TTM) | 3.02 |
Earnings date | 25 Apr 2024 |
Forward dividend & yield | 2.28 (2.12%) |
Ex-dividend date | 22 Feb 2024 |
1y target est | 121.61 |
While AbbVie (ABBV) is set to buy Landos Biopharma, Novo Nordisk (NVO) is set to acquire Cardior Pharmaceuticals. FDA approves J&J's (JNJ) and Merck's (MRK) PAH drugs.
Data from an early-stage study shows that patients who received Viking's (VKTX) orally-administered obesity drug lost up to 5.3% of their body weight after 28 days.
In the most recent trading session, Astrazeneca (AZN) closed at $66.33, indicating a +0.71% shift from the previous trading day.